Best matches for Schütz F[Author]:

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. Motzer RJ et al. N Engl J Med. (2015)

PD-1/PD-L1 Pathway in Breast Cancer. Schütz F et al. Oncol Res Treat. (2017)

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. De Velasco G et al. Cancer Immunol Res. (2017)

  • History not found.

Supplemental Content

Loading ...
Support Center